January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quanex Building Products Corporation (“Quanex” or “the Company”) (NYSE: NX). Investors who purchased Quanex securities prior to December 12, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR). Investors who purchased Jasper securities prior to November 30, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 8, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NANO Nuclear Energy Inc. (“NNE” or “the Company”) (NASDAQ: NNE). Investors who purchased NNE securities prior to May 8, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zenas BioPharma, Inc. (“Zenas” or “the Company”) (NASDAQ: ZBIO). Investors who purchased Zenas securities are encouraged to obtain additional information and assist the investigation. The investigation concerns whether Zenas has violated… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of KBR, Inc. (“KBR” or “the Company”) (NYSE: KBR). Investors who purchased KBR securities prior to May 6, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK). Investors who purchased Cytokinetics securities prior to December 27, 2023, and continue to hold to the present, are encouraged to obtain additional information… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. (“Pacira” or “the Company”) (NASDAQ: PCRX). Investors who purchased Pacira securities prior to August 2, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of DoubleVerify Holdings, Inc. (“DoubleVerify” or “the Company”) (NYSE: DV). Investors who purchased DoubleVerify securities prior to November 10, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PACS Group, Inc. (“PACS” or “the Company”) (NYSE: PACS). Investors who purchased PACS securities prior to April 11, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 7, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sun Communities, Inc. (“Sun Communities” or “the Company”) (NYSE: SUI). Investors who purchased Sun Communities securities prior to February 28, 2019, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (“Danaher” or “the Company”) (NYSE: DHR). Investors who purchased Danaher securities prior to April 21, 2022, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Semler Scientific, Inc. (“Semler” or “the Company”) (NASDAQ: SMLR). Investors who purchased Semler securities prior to March 10, 2021, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of KinderCare Learning Companies, Inc. (“KinderCare” or “the Company”) (NYSE: KLC). Investors who purchased KinderCare securities prior to October 9, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Unicycive Therapeutics, Inc. (“Unicycive” or “the Company”) (NASDAQ: UNCY). Investors who purchased Unicycive securities prior to March 29, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Charter Communications, Inc. (“Charter” or “the Company”) (NASDAQ: CHTR). Investors who purchased Charter securities prior to July 26, 2024, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of SelectQuote, Inc. (“SelectQuote” or “the Company”) (NYSE: SLQT). Investors who purchased SelectQuote securities prior to September 9, 2020, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CTO Realty Growth, Inc. (“CTO” or “the Company”) (NYSE: CTO). Investors who purchased CTO securities prior to February 18, 2021, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flywire Corporation (“Flywire” or “the Company”) (NASDAQ: FLYW). Investors who purchased Flywire securities prior to February 28, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST). Investors who purchased RxSight securities prior to November 7, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Neogen Corporation (“Neogen” or “the Company”) (NASDAQ: NEOG). Investors who purchased Neogen securities prior to January 5, 2025, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fortrea Holdings, Inc. (“Fortrea” or “the Company”) (NASDAQ: FTRE). Investors who purchased Fortrea securities prior to July 3, 2023, and continue to hold to the present, are encouraged to obtain additional… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Digimarc Corporation (“Digimarc” or “the Company”) (NASDAQ: DMRC). Investors who purchased Digimarc securities prior to May 3, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ibotta, Inc. (“Ibotta” or “the Company”) (NYSE: IBTA). Investors who purchased Ibotta securities prior to April 18, 2024, and continue to hold to the present, are encouraged to obtain additional information… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Treace Medical Concepts, Inc. (“Treace Medical” or “the Company”) (NASDAQ: TMCI). Investors who purchased Treace Medical securities prior to May 8, 2023, and continue to hold to the present, are encouraged… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Cerevel Therapeutics Holdings, Inc. (“Cerevel” or “the Company”) (NASDAQ: CERE). Investors who purchased Cerevel securities prior to October 11, 2023, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of MGP Ingredients, Inc. (“MGP Ingredients” or “the Company”) (NASDAQ: MGPI). Investors who purchased MGP Ingredients securities prior to May 4, 2023, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultra Clean Holdings, Inc. (“Ultra Clean” or “the Company”) (NASDAQ: UCTT). Investors who purchased Ultra Clean securities prior to May 6, 2024, and continue to hold to the present, are encouraged… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Maravai LifeSciences Holdings, Inc. (“Maravai” or “the Company”) (NASDAQ: MRVI). Investors who purchased Maravai securities prior to August 7, 2024, and continue to hold to the present, are encouraged to obtain… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Manhattan Associates, Inc. (“Manhattan Associates” or “the Company”) (NASDAQ: MANH). Investors who purchased Manhattan Associates securities prior to October 22, 2024, and continue to hold to the present, are encouraged to… read more
January 1, 2026 |
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQ: TMDX). Investors who purchased TransMedics securities prior to February 3, 2022, and continue to hold to the present, are encouraged to obtain additional… read more